{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T12:08:51Z","timestamp":1776082131389,"version":"3.50.1"},"reference-count":89,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Scleroderma renal crisis (SRC) represents severe, fatal internal organ involvement brought on by systemic sclerosis. A high rate of renal replacement therapy and mortality persists despite various treatments. Depending on the stage of SRC, a vasodilator called angiotensin-converting enzyme inhibitor is the treatment of choice. The efficacy of various other vasodilators (i.e. endothelin-1 receptor antagonist) and complement cascade blocker for SRC have been investigated; however, no randomized control trial has been conducted. A new approach has been proposed for the management of SRC, categorized by specific clinical features of narrowly defined SRC and systemic sclerosis-thrombotic microangiopathy. SRC prophylaxis using angiotensin-converting enzyme inhibitor might be harmful, leading to a poor renal outcome, so the pathogenesis of SRC needs to be clarified in order to identify other possible preventions or therapies.<\/jats:p>","DOI":"10.1093\/mr\/roac028","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T18:42:33Z","timestamp":1648579353000},"page":"12-20","source":"Crossref","is-referenced-by-count":9,"title":["Management review of scleroderma renal crisis: An update with practical pointers"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1964-4389","authenticated-orcid":false,"given":"Chingching","family":"Foocharoen","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, Faculty of Medicine, Khon Kaen University , Khon Kaen, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pantipa","family":"Tonsawan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Faculty of Medicine, Khon Kaen University , Khon Kaen, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patnarin","family":"Pongkulkiat","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, Faculty of Medicine, Khon Kaen University , Khon Kaen, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirirat","family":"Anutrakulchai","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Faculty of Medicine, Khon Kaen University , Khon Kaen, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajanee","family":"Mahakkanukrauh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, Faculty of Medicine, Khon Kaen University , Khon Kaen, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siraphop","family":"Suwannaroj","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, Faculty of Medicine, Khon Kaen University , Khon Kaen, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,3,29]]},"reference":[{"key":"2023011210572309300_R1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0889-857X(03)00016-4","article-title":"Scleroderma renal crisis","volume":"29","author":"Steen","year":"2003","journal-title":"Rheum Dis Clin North Am"},{"key":"2023011210572309300_R2","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/qjmed\/hcm052","article-title":"Scleroderma renal crisis: patient characteristics and long-term outcomes","volume":"100","author":"Penn","year":"2007","journal-title":"QJM"},{"key":"2023011210572309300_R3","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database","volume":"66","author":"Walker","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2023011210572309300_R4","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3899\/jrheum.121380","article-title":"The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review","volume":"40","author":"Muangchan","year":"2013","journal-title":"J Rheumatol"},{"key":"2023011210572309300_R5","first-page":"29","article-title":"Prevalence and clinical features of acute kidney injury in Thai systemic sclerosis patients","volume":"2","author":"Foocharoen","year":"2016","journal-title":"KKU Med J"},{"key":"2023011210572309300_R6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/ard.2006.066985","article-title":"Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients","volume":"67","author":"Teixeira","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2023011210572309300_R7","first-page":"722","article-title":"Crisis as an early presentation of systemic sclerosis","volume":"11","author":"Dolnikov","year":"2020","journal-title":"Isr Med Assoc J IMAJ"},{"key":"2023011210572309300_R8","first-page":"S171","article-title":"Scleroderma renal crisis as an initial presentation of systemic sclerosis: a case report and review of the literature","volume":"33","author":"Logee","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2023011210572309300_R9","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/rheumatology\/keaa401","article-title":"The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i)","volume":"60","author":"Pesta\u00f1a-Fern\u00e1ndez","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2023011210572309300_R10","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.berh.2004.03.002","article-title":"Renal manifestations of systemic autoimmune disease: diagnosis and therapy","volume":"18","author":"O\u2019Callaghan","year":"2004","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2023011210572309300_R11","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/rheumatology\/ker271","article-title":"Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls","volume":"51","author":"Guillevin","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2023011210572309300_R12","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/538589","article-title":"Renal manifestations in scleroderma: evidence for subclinical renal disease as a marker of vasculopathy","volume":"2010","author":"Shanmugam","year":"2010","journal-title":"Int J Rheumatol"},{"key":"2023011210572309300_R13","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrneph.2016.124","article-title":"Scleroderma renal crisis and renal involvement in systemic sclerosis","volume":"12","author":"Woodworth","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"2023011210572309300_R14","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1159\/000507886","article-title":"Renal involvement in systemic sclerosis: an update","volume":"45","author":"Chrabaszcz","year":"2020","journal-title":"Kidney Blood Press Res"},{"key":"2023011210572309300_R15","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.humpath.2008.08.001","article-title":"Renal biopsy findings predicting outcome in scleroderma renal crisis","volume":"40","author":"Batal","year":"2009","journal-title":"Hum Pathol"},{"key":"2023011210572309300_R16","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/ki.1992.65","article-title":"Scleroderma and the kidney","volume":"41","author":"Donohoe","year":"1992","journal-title":"Kidney Int"},{"key":"2023011210572309300_R17","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/bmj.1.5227.713","article-title":"New data on the pathology of \u201cTrue Scleroderma Kidney\u201d","volume":"1","author":"Urai","year":"1961","journal-title":"Br Med J"},{"key":"2023011210572309300_R18","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.semarthrit.2014.12.001","article-title":"Scleroderma renal crisis","volume":"44","author":"Bose","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2023011210572309300_R19","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/IJGM.S221471","article-title":"Renal pathology and clinical associations in systemic sclerosis: a historical cohort study","volume":"12","author":"Tonsawan","year":"2019","journal-title":"Int J Gen Med"},{"key":"2023011210572309300_R20","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/art.40809","article-title":"Generation of a core set of items to develop classification criteria for scleroderma renal crisis using consensus methodology","volume":"71","author":"Butler","year":"2019","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"2023011210572309300_R21","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/j.lpm.2014.02.031","article-title":"Kidney involvement in systemic sclerosis","volume":"43","author":"Steen","year":"2014","journal-title":"Presse Med"},{"key":"2023011210572309300_R22","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/BOR.0b013e3283588dcf","article-title":"Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management","volume":"24","author":"Shanmugam","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"2023011210572309300_R23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/art.1780370110","article-title":"Abnormalities of renal physiology in systemic sclerosis. A prospective study with 10-year followup","volume":"37","author":"Clements","year":"1994","journal-title":"Arthritis Rheum"},{"key":"2023011210572309300_R24","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00005792-198311000-00001","article-title":"Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases","volume":"62","author":"Traub","year":"1983","journal-title":"Medicine (Baltimore)"},{"key":"2023011210572309300_R25","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023011210572309300_R26","doi-asserted-by":"crossref","first-page":"v54","DOI":"10.1093\/rheumatology\/ken307","article-title":"Renal manifestations of systemic sclerosis\u2014clinical features and outcome assessment","volume":"47","author":"Denton","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"2023011210572309300_R27","first-page":"106","article-title":"Group (UKSSG) guidelines on the diagnosis and management of scleroderma renal crisis","volume":"34","author":"Lynch","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2023011210572309300_R28","first-page":"111","article-title":"Pharmacological treatment of scleroderma renal crisis: a systematic literature review","volume":"27","author":"de Zubir\u00eda-Maria","year":"2020","journal-title":"Rev Colomb Reumatol"},{"key":"2023011210572309300_R29","doi-asserted-by":"crossref","first-page":"600","DOI":"10.7326\/0003-4819-133-8-200010170-00010","article-title":"Long-term outcomes of scleroderma renal crisis","volume":"133","author":"Steen","year":"2000","journal-title":"Ann Intern Med"},{"key":"2023011210572309300_R30","doi-asserted-by":"crossref","first-page":"352","DOI":"10.7326\/0003-4819-113-5-352","article-title":"Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors","volume":"113","author":"Steen","year":"1990","journal-title":"Ann Intern Med"},{"key":"2023011210572309300_R31","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0025-6196(12)60418-2","article-title":"Use of captopril as early therapy for renal scleroderma: a prospective study","volume":"60","author":"Beckett","year":"1985","journal-title":"Mayo Clin Proc"},{"key":"2023011210572309300_R32","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972-2002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2023011210572309300_R33","first-page":"S29","article-title":"Assessment of kidney involvement","volume":"21","author":"Steen","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"2023011210572309300_R34","article-title":"Kidney disease in systemic sclerosis (scleroderma), including scleroderma renal crisis - UpToDate [Internet]","year":"2021"},{"key":"2023011210572309300_R35","first-page":"205","article-title":"Resolution of hypertensive encephalopathy and scleroderma renal crisis with an angiotensin receptor blocker","volume":"11","author":"Rajendran","year":"2005","journal-title":"J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis"},{"key":"2023011210572309300_R36","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1053\/j.ajkd.2005.01.007","article-title":"Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade","volume":"45","author":"Cheung","year":"2005","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"2023011210572309300_R37","first-page":"24","article-title":"ACE inhibitors and ARBs: one or the other\u2014not both\u2014for high-risk patients","volume":"58","author":"Misra","year":"2009","journal-title":"J Fam Pract"},{"key":"2023011210572309300_R38","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet Lond Engl"},{"key":"2023011210572309300_R39","first-page":"135","article-title":"Effect of dihydropyridine calcium channel blockers and glucocorticoids on the prevention and development of scleroderma renal crisis in an Italian case series","volume":"31","author":"Montanelli","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2023011210572309300_R40","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000186228","article-title":"Scleroderma hypertensive renal crisis and the changing pattern of mortality in systemic sclerosis (scleroderma)","volume":"57","author":"Langevitz","year":"1991","journal-title":"Nephron"},{"key":"2023011210572309300_R41","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.semarthrit.2012.01.003","article-title":"Treatment of systemic sclerosis complications: what to use when first-line treatment fails\u2014A consensus of systemic sclerosis experts","volume":"42","author":"Walker","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"2023011210572309300_R42","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.coph.2008.01.003","article-title":"Current concepts: renin inhibition in the treatment of hypertension","volume":"8","author":"Gradman","year":"2008","journal-title":"Curr Opin Pharmacol"},{"key":"2023011210572309300_R43","first-page":"21","article-title":"Direct renin inhibition: focus on aliskiren","volume":"13","author":"Pool","year":"2007","journal-title":"J Manag Care Pharm JMCP"},{"key":"2023011210572309300_R44","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.ajkd.2009.02.015","article-title":"Endothelin receptor antagonism and renin inhibition as treatment options for scleroderma kidney","volume":"54","author":"Dhaun","year":"2009","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"2023011210572309300_R45","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2369-13-47","article-title":"Hyponatremia in a patient with scleroderma renal crisis: a potential role of activated renin-angiotensin system","volume":"13","author":"Fukasawa","year":"2012","journal-title":"BMC Nephrol"},{"key":"2023011210572309300_R46","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/ckj\/sfv101","article-title":"Eculizumab for rescue of thrombotic microangiopathy in PM-Scl antibody-positive autoimmune overlap syndrome","volume":"8","author":"Thomas","year":"2015","journal-title":"Clin Kidney J"},{"key":"2023011210572309300_R47","article-title":"Scleroderma renal crisis","volume":"50","author":"Hudson","year":"2021","journal-title":"Presse Medicale Paris Fr 1983"},{"key":"2023011210572309300_R48","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/qjmed\/hct111","article-title":"Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility","volume":"106","author":"Penn","year":"2013","journal-title":"QJM Mon J Assoc Physicians"},{"key":"2023011210572309300_R49","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.ekir.2021.01.021","article-title":"Role of C5 inhibition in idiopathic inflammatory myopathies and scleroderma renal crisis-induced thrombotic microangiopathies","volume":"6","author":"Gouin","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2023011210572309300_R50","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004459","article-title":"Complement activation and effect of eculizumab in scleroderma renal crisis","volume":"95","author":"Devresse","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2023011210572309300_R51","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-1168-x","article-title":"Analysis of complement biomarkers in systemic sclerosis indicates a distinct pattern in scleroderma renal crisis","volume":"18","author":"Okr\u00f3j","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2023011210572309300_R52","article-title":"Scleroderma renal crisis debute with thrombotic microangiopathy: a successful case treated with eculizumab","volume":"2018","author":"Uriarte","year":"2018","journal-title":"Case Rep Nephrol"},{"key":"2023011210572309300_R53","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1177\/1060028020941852","article-title":"Targets and treatment options for thrombotic microangiopathy: caplacizumab and ravulizumab","volume":"55","author":"New Therapeutic","year":"2021","journal-title":"Ann Pharmacother"},{"key":"2023011210572309300_R54","first-page":"1944","article-title":"Effect of iloprost infusion on the resistance index of renal vessels of patients with systemic sclerosis","volume":"24","author":"Scorza","year":"1997","journal-title":"J Rheumatol"},{"key":"2023011210572309300_R55","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O","article-title":"Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis","volume":"41","author":"Steen","year":"1998","journal-title":"Arthritis Rheum"},{"key":"2023011210572309300_R56","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-2141-2","article-title":"ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis-a EUSTAR analysis","volume":"22","author":"B\u00fctikofer","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2023011210572309300_R57","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s40674-014-0004-1","article-title":"Management of renal involvement in scleroderma","volume":"1","author":"Stern","year":"2015","journal-title":"Curr Treat Options Rheumatol"},{"key":"2023011210572309300_R58","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.autrev.2018.03.012","article-title":"Therapy of scleroderma renal crisis: state of the art","volume":"17","author":"Zanatta","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2023011210572309300_R59","first-page":"329","article-title":"Scleroderma renal crisis during intravenous cyclophosphamide pulse therapy for complicated interstitial lung disease was successfully treated with angiotensin converting enzyme inhibitor and plasma exchange","volume":"78","author":"Nagamura","year":"2016","journal-title":"Nagoya J Med Sci"},{"key":"2023011210572309300_R60","first-page":"4398","article-title":"Prognosis of scleroderma renal crisis: a long-term observational study","volume":"27","author":"Cozzi","year":"2012","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"key":"2023011210572309300_R61","article-title":"Poor outcome of peritoneal dialysis during scleroderma renal crisis in scleroderma patients","volume":"101","author":"Siriphannon","year":"2018","journal-title":"J Med Assoc Thai"},{"key":"2023011210572309300_R62","first-page":"236","article-title":"Scleroderma at end stage renal disease in the United States: patient characteristics and survival","volume":"15","author":"Abbott","year":"2002","journal-title":"J Nephrol"},{"key":"2023011210572309300_R63","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1093\/ndt\/gfq861","article-title":"End-stage kidney disease due to scleroderma\u2014outcomes in 127 consecutive ANZDATA registry cases","volume":"26","author":"Siva","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2023011210572309300_R64","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1111\/j.1600-6143.2004.00605.x","article-title":"Kidney transplantation for systemic sclerosis improves survival and may modulate disease activity","volume":"4","author":"Gibney","year":"2004","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg"},{"key":"2023011210572309300_R65","first-page":"256","article-title":"Kidney transplantation in patients with systemic sclerosis: a nationwide multicentre study","volume":"30","author":"Bertrand","year":"2017","journal-title":"Transpl Int Off J Eur Soc Organ Transplant"},{"key":"2023011210572309300_R66","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1002\/art.22965","article-title":"Prevention of vascular damage in scleroderma and autoimmune Raynaud\u2019s phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril","volume":"56","author":"Gliddon","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2023011210572309300_R67","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-019-1467-y","article-title":"Systemic sclerosis medications and risk of scleroderma renal crisis","volume":"20","author":"Gordon","year":"2019","journal-title":"BMC Nephrol"},{"key":"2023011210572309300_R68","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1002\/art.10589","article-title":"Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial","volume":"46","author":"DeMarco","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2023011210572309300_R69","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.semarthrit.2013.09.008","article-title":"International Scleroderma Renal Crisis Study Investigators. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey","volume":"43","author":"Hudson","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"2023011210572309300_R70","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1007\/s00296-013-2691-6","article-title":"Proteinuria in systemic sclerosis: reversal by ACE inhibition","volume":"33","author":"Schuster","year":"2013","journal-title":"Rheumatol Int"},{"key":"2023011210572309300_R71","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3899\/jrheum.171186","article-title":"Risk factors for future scleroderma renal crisis at systemic sclerosis diagnosis","volume":"46","author":"Gordon","year":"2019","journal-title":"J Rheumatol"},{"key":"2023011210572309300_R72","doi-asserted-by":"crossref","DOI":"10.1038\/nrneph.2009.228","article-title":"Aldosterone \u201cescape\u201d vs \u201cbreakthrough\u201d","volume":"6","author":"Schrier","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"2023011210572309300_R73","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s00296-011-1878-y","article-title":"Severe vascular complications in patients affected by systemic sclerosis cyclically treated with iloprost","volume":"32","author":"Caramaschi","year":"2012","journal-title":"Rheumatol Int"},{"key":"2023011210572309300_R74","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1093\/rheumatology\/kez435","article-title":"Classifications of scleroderma renal crisis and reconsideration of its pathophysiology","volume":"58","author":"Yamashita","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2023011210572309300_R75","first-page":"649","article-title":"Kidney disease other than renal crisis in patients with diffuse scleroderma","volume":"32","author":"Steen","year":"2005","journal-title":"J Rheumatol"},{"key":"2023011210572309300_R76","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.927030","article-title":"A 45-year-old man with scleroderma renal crisis associated with a history of systemic sclerosis sine scleroderma","volume":"21","author":"Hansrivijit","year":"2020","journal-title":"Am J Case Rep"},{"key":"2023011210572309300_R77","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.ekir.2019.07.002","article-title":"Scleroderma renal crisis in a systemic sclerosis with anti-PM\/Scl antibodies","volume":"4","author":"Jacquier","year":"2019","journal-title":"Kidney Int Rep"},{"key":"2023011210572309300_R78","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/acr.21964","article-title":"Significance of palpable tendon friction rubs in early diffuse cutaneous systemic sclerosis","volume":"65","author":"Dor\u00e9","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2023011210572309300_R79","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/0002-9343(84)90986-0","article-title":"Factors predicting development of renal involvement in progressive systemic sclerosis","volume":"76","author":"Steen","year":"1984","journal-title":"Am J Med"},{"key":"2023011210572309300_R80","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/art.30111","article-title":"HLA-DRB1*0407 and *1304 are risk factors for scleroderma renal crisis","volume":"63","author":"Nguyen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2023011210572309300_R81","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/anr.1780320911","article-title":"Normotensive renal failure in systemic sclerosis","volume":"32","author":"Helfrich","year":"1989","journal-title":"Arthritis Rheum"},{"key":"2023011210572309300_R82","first-page":"157","article-title":"Glucocorticoids in systemic sclerosis: weighing the benefits and risks \u2013 a systematic review","volume":"31","author":"Iudici","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2023011210572309300_R83","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/1756-185X.13145","article-title":"Risk factors and outcome of Thai patients with scleroderma renal crisis: a disease duration-matched case control study","volume":"20","author":"Wangkaew","year":"2017","journal-title":"Int J Rheum Dis."},{"key":"2023011210572309300_R84","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/rheumatology\/33.1.90","article-title":"Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases","volume":"33","author":"Denton","year":"1994","journal-title":"Br J Rheumatol"},{"key":"2023011210572309300_R85","article-title":"Reversible scleroderma renal crisis after cocaine use","volume":"326","author":"Lam","year":"1992","journal-title":"N Engl J Med"},{"key":"2023011210572309300_R86","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.091048","article-title":"Association of RNA polymerase III antibodies with scleroderma renal crisis","volume":"37","author":"Nguyen","year":"2010","journal-title":"J Rheumatol"},{"key":"2023011210572309300_R87","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.3899\/jrheum.080806","article-title":"Serologic profile and mortality rates of scleroderma renal crisis in Italy","volume":"36","author":"Codullo","year":"2009","journal-title":"J Rheumatol"},{"key":"2023011210572309300_R88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0889-857X(21)00892-9","article-title":"Epidemiology and natural history of systemic sclerosis","volume":"16","author":"Steen","year":"1990","journal-title":"Rheum Dis Clin North Am"},{"key":"2023011210572309300_R89","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.1780270202","article-title":"Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis","volume":"27","author":"Steen","year":"1984","journal-title":"Arthritis Rheum"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roac028\/43350008\/roac028.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/1\/12\/48626578\/roac028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/1\/12\/48626578\/roac028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T12:18:46Z","timestamp":1673525926000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/33\/1\/12\/6555653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,29]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,3,29]]},"published-print":{"date-parts":[[2023,1,3]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roac028","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,3,29]]}}}